B2M and non-Hodgkin lymphoma: Johnson and colleagues [17] found that the outcome of chemotherapy in patients with aggressive non-Hodgkin lymphomas correlates with initial values of β2M: in the group with normal values, 70% of patients reached a clinical remission, and in the group of patients with elevated β2M, only 37% of patients achieved a clinical remission (P < 0.001).